

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David James Hallett, et al.
Int'l Appln. No. : PCT/GB 00/ 03350
Int'l Date Filed : 30 August 2000 (30/08/2000)
Serial No. : (To be assigned) Case No.: T1502
Filed : (To be assigned)
For : IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS
FOR GABA RECEPTORS

The Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT February 25, 2002
EXPRESS MAIL NO. EL 920630186 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231
MAILED BY Christine C. [Signature]
DATE February 25, 2002

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the references that are cited on the attached form PTO-1449 are enclosed herewith.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By



J. Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: February 25, 2002

10070026-022502

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

Application Number	JP 2002-000000 Rec'd PCT/PTO 25 FEB 2002
Filing Date	
First Named Inventor	David James Halett, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	T1502

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Date Considered

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 10/05/2001